Therapeutic Follow-up of Antibiotics in Pediatric Intensive Care (STAR-P)

Centre Hospitalier Universitaire de la Réunion

Status: Not yet enrolling

Conditions: Intensive Care Units, Pediatric

Treatments: Other: Antibiotics Dosing

Study type: Observational

Funder types: Other

Identifiers

NCT05354635

2022/CHU/05

Details and patient eligibility

About

Currently, recommendations for antibiotic testing (ATS) in adult intensive care have been published. The 2018 SFAR and the Abdul- Aziz et al expert conference recommend routine testing for β-lactams, aminoglycosides, linezolid, and vancomycin and provide plasma concentration goals. No recommendations have been made for the pediatric intensive care unit (PICU) population. However, several articles report suboptimal plasma concentrations for the most frequently used antibiotics in PICU. The University Hospital of Reunion is the reference center for the western region of the Indian Ocean. This region presents a large mixed population due to the migratory flow, as well as a specific bacterial ecology. This suggests that the data already collected on antibiotic dosage in other European studies may not be fully extrapolated to Reunion Island.

It is in this context that we will study the plasma concentration of antibiotics for all children who received the most commonly used antibiotics (β-lactams, linezolid, vancomycin, and aminoglycosides) during their hospitalization in PICU.

Enrollment: 280 estimated patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any child hospitalized in the pediatric intensive care unit of the CHU Nord de La Réunion,
• Age is less than 18 years,
• Having started a curative antibiotic therapy by β-lactam, linezolid, vancomycin or aminosides.
• For whom a non-opposition has been collected orally from both or one of the child's legal guardians and from the child himself (if applicable),
• Covered by Social Security.

Exclusion criteria

-Patients on prophylactic antibiotic therapy